title: Interleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient.
abstract: Biallelic BRCA2 mutations occur in 2% of patients with Fanconi anemia and are associated with a high risk of acute leukemia at an early age and a poor prognosis. For the first time, we report the use of interleukin-2 to stimulate a graft-versus-leukemia effect and induce complete remission in a patient with BRCA2 Fanconi anemia and refractory acute myelogenous leukemia, suggesting the potential of immunotherapy in this setting. Interleukin-2 was associated with significant infusion-related toxicity.
authors.affiliation: *School of Clinical Medicine, University of Cambridge, Cambridge, UK †Division of Blood and Marrow Transplantation, Levine Children's Hospital, Charlotte, NC.
authors.forename: Crystal J J
authors.initials: CJ
authors.lastname: Yeo
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Gilman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D005199:Fanconi Anemia / Q000150:complications / Q000235:genetics*; D005260:Female; D024522:Genes, BRCA2; D020544:Graft vs Leukemia Effect / Q000187:drug effects*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2